These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17215475)

  • 21. Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.
    Mandrioli R; Protti M; Mercolini L
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):149-74. PubMed ID: 25483358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
    Toren P; Ratner S; Laor N; Weizman A
    Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of bipolar mania with atypical antipsychotics.
    Chengappa KN; Suppes T; Berk M
    Expert Rev Neurother; 2004 Nov; 4(6 Suppl 2):S17-25. PubMed ID: 16279862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematized Review of Atypical Antipsychotics in Pregnant Women: Balancing Between Risks of Untreated Illness and Risks of Drug-Related Adverse Effects.
    Tosato S; Albert U; Tomassi S; Iasevoli F; Carmassi C; Ferrari S; Nanni MG; Nivoli A; Volpe U; Atti AR; Fiorillo A
    J Clin Psychiatry; 2017 May; 78(5):e477-e489. PubMed ID: 28297592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The metabolic syndrome and antipsychotics in children and adolescents].
    Dori N; Green T
    Harefuah; 2011 Oct; 150(10):791-6, 814, 813. PubMed ID: 22111125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and tolerability of atypical antipsychotics in bipolar disorder.
    Seemüller F; Forsthoff A; Dittmann S; Born C; Bernhard B; Severus WE; Grunze H
    Expert Opin Drug Saf; 2005 Sep; 4(5):849-68. PubMed ID: 16111448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics.
    Jiang Y; McCombs JS; Park SH
    CNS Drugs; 2017 Apr; 31(4):319-326. PubMed ID: 28290080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.
    Henderson DC; Doraiswamy PM
    J Clin Psychiatry; 2008; 69 Suppl 1():32-44. PubMed ID: 18484806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotics from theory to practice: integrating clinical and basic data.
    Tandon R; Milner K; Jibson MD
    J Clin Psychiatry; 1999; 60 Suppl 8():21-8. PubMed ID: 10335668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics.
    Cohrs S
    CNS Drugs; 2008; 22(11):939-62. PubMed ID: 18840034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine: a 5-year perspective.
    Littrell KH; Petty RG; Wolf NM
    Expert Rev Neurother; 2006 Jun; 6(6):811-21. PubMed ID: 16784405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotic tolerability and switching strategies in bipolar disorder.
    Liauw SS; McIntyre RS
    Expert Opin Pharmacother; 2010 Dec; 11(17):2827-37. PubMed ID: 20726821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype.
    Nussbaum LA; Dumitraşcu V; Tudor A; Grădinaru R; Andreescu N; Puiu M
    Rom J Morphol Embryol; 2014; 55(3):877-84. PubMed ID: 25329115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward convergence in the medication treatment of bipolar disorder and schizophrenia.
    Citrome L; Goldberg JF; Stahl SM
    Harv Rev Psychiatry; 2005; 13(1):28-42. PubMed ID: 15804932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental antipsychotics and metabolic adverse effects--findings from clinical trials.
    Tschoner A; Fleischhacker WW; Ebenbichler CF
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1041-8. PubMed ID: 19777392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.